When multiple myeloma relapses
RESPOND with higher response rates with Kyprolis®-based regimen (vs Rd)
KRd overall response rate
In the ASPIRE trial, almost 9 out of 10 patients achieved a response with KRd.1
Adapted from Stewart et al.1
Kyprolis®-based regimens consistently provided benefit to relapsed multiple myeloma patients, across different measures of response1
Kyprolis® has a tolerable safety profile in combination with Rd
*Descriptive P value.
Please read the SmPC for full comprehensive safety information
References
- Stewart AK et al. N Engl J Med 2015;372:142–152.
